These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 27143896)

  • 21. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
    Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cochrane Review: Osmotic and stimulant laxatives for the management of childhood constipation (Review).
    Gordon M; Naidoo K; Akobeng AK; Thomas AG
    Evid Based Child Health; 2013 Jan; 8(1):57-109. PubMed ID: 23878124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
    Mahableshwarkar AR; Zajecka J; Jacobson W; Chen Y; Keefe RS
    Neuropsychopharmacology; 2015 Jul; 40(8):2025-37. PubMed ID: 25687662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders.
    Findling RL; Robb AS; DelBello MP; Huss M; McNamara NK; Sarkis EH; Scheffer RE; Poulsen LH; Chen G; Lemming OM; Auby P
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):47-54. PubMed ID: 29035574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vortioxetine for depression in adults: A systematic review and dose-response meta-analysis of randomized controlled trials.
    Yang X; Fang S; Lyu W; Hu Y; Xu H; Jiang X; Zhao Y; Zhang Y; Li J; Kuang W
    Psychiatry Clin Neurosci; 2024 Jul; ():. PubMed ID: 38957929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant therapy with antidepressants for the management of inflammatory bowel disease.
    Mikocka-Walus A; Prady SL; Pollok J; Esterman AJ; Gordon AL; Knowles S; Andrews JM
    Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012680. PubMed ID: 30977111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Chen Y
    Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapist-supported Internet cognitive behavioural therapy for anxiety disorders in adults.
    Olthuis JV; Watt MC; Bailey K; Hayden JA; Stewart SH
    Cochrane Database Syst Rev; 2015 Mar; (3):CD011565. PubMed ID: 25742186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amitriptyline versus placebo for major depressive disorder.
    Leucht C; Huhn M; Leucht S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009138. PubMed ID: 23235671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Second-generation antidepressants for preventing seasonal affective disorder in adults.
    Gartlehner G; Nussbaumer B; Gaynes BN; Forneris CA; Morgan LC; Kaminski-Hartenthaler A; Greenblatt A; Wipplinger J; Lux LJ; Sonis JH; Hofmann J; Van Noord MG; Winkler D
    Cochrane Database Syst Rev; 2015 Nov; (11):CD011268. PubMed ID: 26558418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological treatment for memory disorder in multiple sclerosis.
    He D; Zhang Y; Dong S; Wang D; Gao X; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008876. PubMed ID: 24343792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapist-supported Internet cognitive behavioural therapy for anxiety disorders in adults.
    Olthuis JV; Watt MC; Bailey K; Hayden JA; Stewart SH
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD011565. PubMed ID: 26968204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
    Baune BT; Sluth LB; Olsen CK
    J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine.
    Orsolini L; Tomasetti C; Valchera A; Iasevoli F; Buonaguro EF; Vellante F; Fornaro M; Fiengo A; Mazza M; Vecchiotti R; Perna G; de Bartolomeis A; Martinotti G; Di Giannantonio M; De Berardis D
    Expert Rev Neurother; 2016 May; 16(5):483-95. PubMed ID: 27050932
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.